Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
© Life Molecular Imaging

Life Molecular Imaging (LMI) joins DPUK as an associate partner, collaborating specifically with institutions in the Imaging Network, including UCL, Imperial, Cambridge and Manchester universities, as part of the Tau-PET study. The multi-partner team are working together to create an important resource for modelling the earliest stages of Alzheimer’s disease.

New expertise for DPUK

LMI (part of the Alliance Medical Group) brings industry expertise in molecular imaging of degenerative brain disease to the Tau-PET study. This study will benefit from a key investigational compound used for PET imaging which is being developed by LMI. 

This new compound has been shown to bind to the ‘tau’ protein meaning that the scientists can use it to map the build up of tau, in addition to the existing scans they have of the amyloid protein in the study group. Both proteins are known hallmarks of Alzheimer’s disease. This imaging study is enabling scientists to better understand the mechanisms and processes at play in the brain leading to progressive cognitive decline and dementia in Alzheimer’s disease.

Detailed imaging of amyloid and tau

The Tau-PET study will see researchers carry out additional PET scanning of participants in two existing health study cohorts – EPAD and PREVENT. The extra information they collect on the 'tau' protein, when combined with existing data from these study groups, will create a very rich dataset for modelling the early stages of Alzheimer's disease and subsequent dementia.

Andrew Stephens, LMI's Chief Medical Officer, says: “LMI is excited to contribute to this unique study as a research partner with DPUK. The Tau-PET imaging study will generate critical information of the earliest stages of Alzheimer’s disease. Over 50 million people are living with dementia worldwide. We desperately need to develop treatments. This can only come from an in depth understanding of the disease at its earliest manifestation”.

This partnership with LMI will allow us to use a cutting-edge technique to investigate the earliest stages of Alzheimer’s Disease. This kind of collaborative research, working with teams from across the UK, will help us to understand the key mechanisms behind Alzheimer’s, and, in the longer term, develop effective treatments.
– Dr Paresh Malhotra, DPUK clinical scientist and study PI. 

DPUK director John Gallacher says:Bringing industry expertise and techniques to bear on dementia research is adding real value to cohort data. LMI’s imaging techniques reveal molecular changes as the disease progresses which, when coupled with rich cohort data, allows us to model the early stages of Alzheimer’s disease and dementia."

Find out more about DPUK's Imaging network.

Find out more about the PET imaging compound being developed by LMI.